Curative vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 52)
Curative logo

Curative

ChallengerHealthcare

AI-Driven Employer Health Insurance

Curative is an AI-powered health insurance plan for employers that eliminates copays and deductibles; raised $153M Series B at $1B valuation; partners with employers to offer zero-cost primary and specialist care using a curated provider network.

AI VisibilityBeta
Overall Score
C52
Category Rank
#312 of 596
AI Consensus
75%
Trend
stable
Per Platform
ChatGPT
56
Perplexity
46
Gemini
52

About

Curative is a health insurance startup redesigning employer-sponsored health benefits by offering a plan that eliminates copays, deductibles, and coinsurance for employees who use Curative's curated network of primary care providers, specialists, and hospitals. Founded in 2020 in Austin, Texas by Fred Turner (who previously ran Curative's COVID testing business at massive scale), the company raised $153 million in a Series B round at a $1 billion valuation. Curative's model is built on the conviction that removing financial friction from healthcare access — specifically the upfront costs that deter people from seeking preventive and early care — ultimately reduces total healthcare spend for employers.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

52
Overall Score
90
#312
Category Rank
#2
75
AI Consensus
83
stable
Trend
stable
56
ChatGPT
92
46
Perplexity
93
52
Gemini
89
55
Claude
96
55
Grok
95

Key Details

Category
AI-Driven Employer Health Insurance
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.